Amphastar Pharmaceuticals Stock News

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters sold 1,744 shares of the companys stock in a transaction dated Thursday, December 16th. The shares were sold at an average price of $22.40, for a total value of $39,065.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available []

Here is how AmerisourceBergen (ABC) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. Amphastar (AMPH), Sanderson Farms (SAFM) and Sensus Healthcare (SRTS) are well poised to gain.

It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. Amphastar (AMPH), Sanderson Farms (SAFM) and Sensus Healthcare (SRTS) are well poised to gain.

When screening the market for bargain opportunities, investors may want to look for stocks whose trailing 12-month and forward price-earnings to growth (PEG) ratios are at or below 1.5 as of Dec. 13,

Complete study of the global Isoprenaline market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present

Amphastar Pharmaceuticals (AMPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Amphastar Pharmaceuticals (AMPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Key Companies Covered in the Heparin Market Research Report Are GlaxoSmithKline plc, Pfizer Inc., Aspen Holdings, Baxter International Inc., Fresenius Kabi AG, Amphastar Pharmaceuticals, Inc., Mylan N.V., Sanofi, LEO Pharma A/S, B.Braun Melsungen AG, and other key market players. Key Companies Covered in the Heparin Market Research Report Are GlaxoSmithKline plc, Pfizer Inc., Aspen Holdings, Baxter International Inc., Fresenius Kabi AG, Amphastar Pharmaceuticals, Inc., Mylan N.V., Sanofi, LEO Pharma A/S, B.Braun Melsungen AG, and other key market players.

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Amphastar Pharmaceuticals (AMPH), AMN Healthcare (AMN) & Sensus Healthcare (SRTS) are well poised to gain.

State of Alaska Department of Revenue raised its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,978 shares of the companys stock after buying an additional 1,600 shares during the []

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Amphastar Pharmaceuticals (AMPH), AMN Healthcare (AMN) & Sensus Healthcare (SRTS) are well poised to gain.

Equities research analysts expect that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will announce sales of $111.62 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Amphastar Pharmaceuticals earnings, with estimates ranging from $109.00 million to $116.39 million. Amphastar Pharmaceuticals reported sales of $95.92 million during the same quarter last year, []

UBS Asset Management Americas Inc. raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,811 shares of the companys stock after purchasing an additional 2,724 shares during the quarter. UBS Asset Management []

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Commun